Parental Perceived Benefits of OROS-Methylphenidate Treatment for the Child with Attention-Deficit/Hyperactivity Disorder and for Parents Themselves

Abstract

Introduction:

Given the shortage of studies on parental perceived benefits of OROS-methylphenidate treatment in Asian populations, we assessed parental response to OROS-methylphenidate treatment of Korean children with attention-deficit/hyperactivity disorder (ADHD), in relation to children’s academic performance and behavioral symptoms as well as parental rearing stress and depressive symptoms.

Methods:

We enrolled 132 medication-naïve children with ADHD into a multicenter, open-label, 12-week trial of OROS-MPH. The outcome measures were the ADHD rating scale-IV (ADHD-RS), the comprehensive attention test and academic performance rating scale, and the clinical global impression (CGI)-severity/improvement instrument (for the children) and Beck depression inventory and parenting stress index (for their parents).

Results:

We found parent-perceived improvements in children’s ADHD-related behavioral symptoms and academic function and their parents' depressive symptoms and parenting stress. Investigator-rated ADHD symptoms and subjects' neuropsychological function were also improved (p<0.001).

Discussion:

Parents of Korean children with ADHD perceive that OROS-methylphenidate treatment improves their children’s academic function and behavior as well as their own child-rearing stress and emotional state. These findings must be interpreted with caution, due to a non-comparative open-label trial.

Key words

ADHD - OROS methylphenidate - parents - academic performance

• References

• 1 Cohen RAMP, Jenkins MA, Paul RH. Disorders of Attention in Clinical Neuropsychology. American Psychiatric Association; 2006
• 2 Luna B, Thulborn KR, Munoz DP et al. Maturation of widely distributed brain function subserves cognitive development. Neuroimage 2001; 13: 786-793
• 3 Schulz KP, Fan J, Tang CY et al. Response inhibition in adolescents diagnosed with attention deficit hyperactivity disorder during childhood: an event-related FMRI study. Am J Psychiatry 2004; 161: 1650-1657
• 4 Shaywitz BA, Fletcher JM, Shaywitz SE. Attention-deficit/hyperactivity disorder. Adv Pediatr 1997; 44: 331-367
• 5 Hinshaw SP. Externalizing behavior problems and academic under­achievement in childhood and adolescence: causal relationships and underlying mechanisms. Psychol Bull 1992; 111: 127-155
• 6 Johnston C. Parent characteristics and parent-child interactions in families of nonproblem children and ADHD children with higher and lower levels of oppositional-defiant behavior. J Abnorm Child Psychol 1996; 24: 85-104
• 7 Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001; 4: 183-207
• 8 Pelham Jr WE, Lang AR. Can your children drive you to drink? Stress and parenting in adults interacting with children with ADHD. Alcohol Res Health 1999; 23: 292-298
• 9 Podolski CL, Nigg JT. Parent stress and coping in relation to child ADHD severity and associated child disruptive behavior problems. J Clin Child Psychol 2001; 30: 503-513
• 10 Nutt DJ, Fone K, Asherson P et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007; 21: 10-41
• 11 Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894-921
• 12 Abikoff HB, Vitiello B, Riddle MA et al. Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007; 17: 581-592
• 13 Adler LA, Zimmerman B, Starr HL et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29: 239-247
• 14 Gau SS, Shen HY, Soong WT et al. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006; 16: 441-455
• 15 Medori R, Ramos-Quiroga JA, Casas M et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63: 981-989
• 16 Steele M, Weiss M, Swanson J et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006; 13: e50-e62
• 17 Stein MA, Sarampote CS, Waldman ID et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: e404
• 18 Wilens TE, Biederman J, Lerner M. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24: 36-41
• 19 Wilens TE, McBurnett K, Bukstein O et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160: 82-90
• 20 Wolraich ML, Greenhill LL, Pelham W et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883-892
• 21 Chou WJ, Chou MC, Tzang RF et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 2009; 63: 167-175
• 22 Lee SI, Hong SD, Kim SY et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 210-216
• 23 Yang P, Hsu HY, Chiou SS et al. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample. Aust N Z J Psychiatry 2007; 41: 998-1004
• 24 Pi EH, Simpson GM. Cross-cultural psychopharmacology: a current clinical perspective. Psychiatr Serv 2005; 56: 31-33
• 25 Kaufman J, Birmaher B, Brent D et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-988
• 26 Kim YS, Cheon KA, Kim BN et al. The reliability and validity of Kiddie-schedule for affective disorders and schizophrenia-present and lifetime version – Korean version (K-SADS-PL-K). Yonsei Med J 2004; 45: 81-89
• 27 DuPaul GJ. Parent and teacher ratings of ADHD symptoms – Psychometric properties in a community-based sample. J Clin Child Psychol 1991; 20: 245-253
• 28 So YK, Noh JS, Kim YS et al. The reliability and validity of Korean parent and teacher ADHD rating scale. J Korean Neuropsychiatr Assoc 2002; 41: 283-289
• 29 DuPaul GJ, Rapport M, Perriello L. Teacher rating of academic skills: The development of the Academic Performance Rating Scales. School Psychol Rev 1991; 20: 284-300
• 30 Seo MK, Kim CN. A comparison of public stigma against the mental patients and mental patients’ perceived stigma. J Korean Neuropsychiatr Assoc 2006; 44: 371-375
• 31 Cho YK, Ha EH. Validation Study of the Korean Academic Performance Rating Scale (K-APRS) Parent Form. Korean J Clin Psychol 2009; 28: 1173-1189
• 32 Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
• 33 Han HM, Yom TH, Shin YW et al. Korean standardization study of Beck Depression Inventory: For normal group (1). Korean J Neuropsychiatric Ass 1986; 25: 487-502
• 34 Abidin RR. Parenting Stress Index Short Form. Charlottesville, VA: Pediatric Psychology Press; 1999
• 35 Shin SJ, Chung MJ. Effects of Stress, Social Support and Efficacy on Mothers’ Parenting Behaviors. Korean J Association Child Studies 1998; 19: 27-42
• 36 National Institute of Mental Health . CGI, Clinical Global Impressions. Chevy Chase, Maryland: National Institute of Mental Health; 1970
• 37 Sung YS, Cho SC. The standardization of Korean CGI-I and CGI-S in children. In: Proceedings of Annual Meeting of Korean Neuropsychiatric Association 1995;
• 38 Yoo HK, Lee JS, Kang SH et al. Standardization of the Comprehensive Attention Test for the Korean Children and Adolescents. J Kor Acad Child Adolesc Psychiatry 2009; 20: 68-75
• 39 Barkley RA, McMurray MB, Edelbrock CS et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184-192
• 40 Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther 2006; 28: 1892-1908
• 41 Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105
• 42 Wilens T, Pelham W, Stein M et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003; 42: 424-433
• 43 Collazo Y, Tam R, Sramek J et al. Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med 1996; 63: 310-313
• 44 Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001; 62 (Suppl. 13) 13-19 discussion 11–20
• 45 Hwang JW, Kim BN, Cho SC. Compliance study of methylphenidate IR in the treatment of ADHD. Korean J Child Adol Psychiatr 2004; 15: 160-167
• 46 Shin JY, Yang JW, Jang WS et al. Prescription status and efficacy of OROS-MPH and parent perception in children with attention deficit hyperactivity disorder: multi-center, observational study during 4 weeks. Korean J Psychopharmacol 2007; 18: 50-59
• 47 Carlson CL, Pelham Jr WE, Milich R et al. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 1992; 20: 213-232
• 48 Francis S, Fine J, Tannock R. Methylphenidate selectively improves story retelling in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11: 217-228
• 49 Hechtman L, Abikoff H, Klein RG et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43: 812-819
• 50 Jacobvitz D, Sroufe LA, Stewart M et al. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990; 29: 677-688
• 51 Tannock R, Schachar RJ, Carr RP et al. Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics 1989; 84: 648-657
• 52 Van der Oord S, Prins PJ, Oosterlaan J et al. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008; 28: 783-800
• 53 van der Meere J, Gunning B, Stemerdink N. The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD. J Child Psychol Psychiatry 1999; 40: 291-298
• 54 Byrne JM, Bawden HN, DeWolfe NA et al. Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol 1998; 20: 613-627
• 55 Musten LM, Firestone P, Pisterman S et al. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997; 36: 1407-1415
• 56 Brodeur DA, Pond M. The development of selective attention in children with attention deficit hyperactivity disorder. J Abnorm Child Psychol 2001; 29: 229-239
• 57 Durukan I, Turkbay T, Congologlu A. The effects of methylphenidate on various components of visual attention in children with attention-deficit hyperactivity disorder. Turk Psikiyatri Derg 2008; 19: 358-364
• 58 Fernandez-Jaen A, Fernandez-Mayoralas DM, Pardos A et al. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation. Adv Ther 2009; 26: 1097-1110
• 59 Scheres A, Oosterlaan J, Swanson J et al. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. J Abnorm Child Psychol 2003; 31: 105-120
• 60 Breen MJ, Barkley RA. Child psychopathology and parenting stress in girls and boys having attention deficit disorder with hyperactivity. J Pediatr Psychol 1988; 13: 265-280
• 61 Barkley RA, Karlsson J, Pollard S et al. Developmental changes in the mother-child interactions of hyperactive boys: effects of two dose levels of Ritalin. J Child Psychol Psychiatry 1985; 26: 705-715
• 62 Kent MA, Camfield CS, Camfield PR. Double-blind methylphenidate trials: practical, useful, and highly endorsed by families. Arch Pediatr Adolesc Med 1999; 153: 1292-1296
• 63 Cunningham CE, Siegel LS, Offord DR. A dose-response analysis of the effects of methylphenidate on the peer interactions and simulated classroom performance of ADD children with and without conduct problems. J Child Psychol Psychiatry 1991; 32: 439-452
• 64 Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol 2003; 13: 29-40
• 65 Maayan L, Paykina N, Fried J et al. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. J Child Adolesc Psychopharmacol 2009; 19: 147-153
• 66 Retz W, Rosler M, Ose C et al. Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 2010;
• 67 [Anonymous] . National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762-769
• 68 Faraone SV, Biederman J, Morley CP et al. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 994-1009
• 69 Spencer TJ, Faraone SV, Biederman J et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?. J Am Acad Child Adolesc Psychiatry 2006; 45: 527-537
• 70 Darmansjah I, Muchtar A. Dose-response variation among different populations. Clin Pharmacol Ther 1992; 52: 449-452
• 71 Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219
• 72 Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 2008; 17: 475-490 xi-xii
• 73 Weiss M, Hechtman L, Turgay A et al. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17: 675-688